Earlier this month, another press release announced promising results from a Phase 3 clinical study for the drug Denufosol. The drug, taken by inhaling with a nebulizer, offers improved chloride transport in the lungs to improve mucus consistency and aid in airway clearance. This treatment functions by activating alternate chloride channels, thus increasing the main function that is affected by defective CFTR genes.
This positive announcement of another treatment for CF gives even more evidence that all the funding going towards CF research is paying off. Hopefully further exciting results will come from the additional studies on this drug, and the others in the pipeline!
You can read the full press release from Inspire Pharmaceuticals here.
{ 1 trackback }
{ 0 comments… add one now }